Drug Trial Radar · NCT03165734
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
407
Actual
Start
Jun 26, 2017
Primary completion
Oct 5, 2026
Study completion Oct 13, 2028
Sponsor
- Lead sponsor
- Swedish Orphan BiovitrumIndustry
- Sponsor type
- Industry
- Collaborators
- PSI CRO
- First posted
- May 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count \<50,000/μL). Approximately 399 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 266 patients) or to P/C therapy (approximately 133 patients) Condition or disease: Primary Myelofibrosis/Post-Polycythemia Vera Myelofibrosis/ Post-essential Thrombocythemia Myelofibrosis Intervention/treatment: Drug-Pacritinib
Conditions
- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
Interventions
PacritinibDrug
Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsule contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base
Physician's Choice medicationsDrug
Physician's Choice medications will be selected and administered according to the investigator's judgement. Investigators can select individual P/C agents but cannot combine agents or give them sequentially.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Spleen volumeTime frame: From baseline at 24 weeks
- Total Symptom Score (TSS) (excluding tiredness)Time frame: From baseline at Week 24
Locations
207 sites in 24 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham, (UAB) Hospital, Comprehensive Cancer Center
Birmingham, Alabama
Mayo Clinic Hospital
Phoenix, Arizona
City of Hope
Duarte, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
UCLA David Geffen School of Medicine
Los Angeles, California
University of Colorado Cancer Center
Aurora, Colorado
Rocky Mountain Cancer Centers (US Oncology/McKesson)
Boulder, Colorado
Yale School of Medicine
New Haven, Connecticut
Georgetown University Hospital
Washington D.C., District of Columbia
George Washington University-Medical Faculty Associates
Washington D.C., District of Columbia
Cleveland Clinic Florida
Weston, Florida
Northwestern Memorial Hospital
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
The University of Chicago Medical Center
Chicago, Illinois
University of Kansas Cancer Center and Medical Pavilion
Westwood, Kansas
Ochsner Medical Center
New Orleans, Louisiana
Saint Agnes Hospital
Baltimore, Maryland
Johns Hopkins University
Baltimore, Maryland
American Oncology Partners of Maryland, PA
Bethesda, Maryland
Regional Cancer Care Associates LLC - CCBD Division
Bethesda, Maryland
Maryland Oncology Hematology, PA- Columbia
Columbia, Maryland
Michigan Medicine Hematology Clinic-Rogel Cancer Center
Ann Arbor, Michigan
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan
Washington University School of Medicine-Siteman Cancer Center
St Louis, Missouri
Comprehensive Cancer Centers of Nevada- Twain Office
Las Vegas, Nevada
Hackensack University Medical Center
Hackensack, New Jersey
Columbia University Medical Center
New York, New York
Weill Cornell Medical College
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Memorial Sloan -Kettering Cancer Center
New York, New York
University of Rochester
Rochester, New York
Duke University Hospital
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
The Sarah Cannon Research Institute-Tennessee Oncology
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Mays Cancer Center
San Antonio, Texas
Texas Oncology- San Antonio
San Antonio, Texas
Showing 40 of 207 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.